Table V.
Comparison of pharmacokinetic parameters between the Western and the Japanese analyses. The population estimates are reported along with the estimated interindividual variability expressed as CV in brackets, when it was estimated in the analysis. The parameter estimates for the Japanese analysis were reported in [9].
| Compound | Parameter | Western analysis | Japanese analysis |
|---|---|---|---|
| CDHP | kabs,CDHP (hr−1) | 1.2 (83%) | 1.2(114%) |
| CLCDHP/F (L.hr−1) | 6.2*BSA (34%) | 10.9 (41%) | |
| Vd,CDHP/F (L) | 18.8*BSA (20%) | 51.4 (29%) | |
| FT | kabs,FT (hr−1) | 1.4 (103%) | 0.9 (98%) |
| CLFT/F (L.hr−1) | 2.9*BSA (31%) | 1.2*BSA (40%) | |
| Vd,FT/F (L) | 16.0*BSA (27%) | 13.8*BSA (19%) | |
| 5-FU | CL0,5–FU/F (L.hr−1) | 146*BSA (16%) | 170*BSA (22%) |
| Vd,5–FU/F (L) | 11.5*BSA(16%) | 9.4*BSA (22%) | |
| ki, (mg.L−1) | 0.04 (−) | 0.03 (−) | |
| Oteracil | kabs,oxo (hr−1) | gastric: 2.1 (82%) | 1.0,1.6† (71%) |
| other: 0.9 (82%) | 0.5,0.8† (71%) | ||
| CLoxo/F (L.hr−1) | gastric: 85*BSA (81%) | 55.4*BSA,71.5*BSA† (81%) | |
| other: 163*BSA (81%) | 101*BSA,130*BSA† (81%) | ||
| Vd,oxo/F (L) | gastric: 293*BSA (72%) | 231*BSA,298*BSA† (70%) | |
| other: 561*BSA (72%) | 419*BSA,541*BSA† (70%) |
†
the two values given for the parameters of oteracil in Japanese patients correspond to two groups with ages respectively over 65 and under 65.